A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2009
12/01/2009	CA2555213C Nucleoside phosphonate derivatives useful in the treatment of hiv infections
12/01/2009	CA2523246C Formation of strong superporous hydrogels
12/01/2009	CA2521258C 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
12/01/2009	CA2508262C Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction
12/01/2009	CA2492196C Sulfotransferase inhibitors
12/01/2009	CA2461100C 4-imidazolin-2-one compounds
12/01/2009	CA2442311C Amorphous cefditoren pivoxil composition and process for producing the same
12/01/2009	CA2432121C Nitric oxide synthase inhibitor phosphate salt
12/01/2009	CA2418348C Oil/fat composition
12/01/2009	CA2407210C Liposome drug delivery
12/01/2009	CA2399426C Endoparasiticidal gel composition
12/01/2009	CA2389412C N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
12/01/2009	CA2384718C Prostaglandin derivatives
12/01/2009	CA2376593C Method of particle formation
12/01/2009	CA2374317C Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
12/01/2009	CA2361802C O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically acceptable salts and process for preparing the same
12/01/2009	CA2315237C Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
12/01/2009	CA2305533C Multilamellar coalescence vesicles (mlcv) containing biologically active compounds
12/01/2009	CA2303229C Pentopyranosylnucleoside, its preparation and use
12/01/2009	CA2265547C Method of treating endothelial injury
12/01/2009	CA2264556C Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
11/2009
11/26/2009	WO2009143515A2 Treatment using continuous low dose application of sugar analogs
11/26/2009	WO2009143507A2 Silent desensitizers of neuronal nachr and methods of use thereof
11/26/2009	WO2009143485A1 Diazonamide analogs
11/26/2009	WO2009143477A1 Heterocycles as protein kinase inhibitors
11/26/2009	WO2009143457A2 Vaccine composition containing synthetic adjuvant
11/26/2009	WO2009143454A2 Combination antitumor therapy
11/26/2009	WO2009143445A1 Aza-beta-carbolines and methods of using same
11/26/2009	WO2009143404A1 Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
11/26/2009	WO2009143403A1 Combination therapy for the management hypertension
11/26/2009	WO2009143389A1 Phosphorous derivatives as kinase inhibitors
11/26/2009	WO2009143372A2 Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof
11/26/2009	WO2009143371A2 COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
11/26/2009	WO2009143365A2 Compositions and methods of treatment using modulators of motoneuron diseases
11/26/2009	WO2009143363A2 Functional metabolomics coupled microfluidic chemotaxis device and identification of novel cell mediators
11/26/2009	WO2009143361A1 Amido anti-viral compounds
11/26/2009	WO2009143317A1 Triazine compounds as p13 kinase and mtor inhibitors
11/26/2009	WO2009143313A1 Triazine compounds as p13 kinase and mtor inhibitors
11/26/2009	WO2009143292A2 Method of treating pneumoconiosis with oligodeoxynucleotides
11/26/2009	WO2009143290A2 Inducing cell death by inhibiting adaptive heat shock response
11/26/2009	WO2009143288A1 Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
11/26/2009	WO2009143266A1 Targeting the efflux systems of mycobacterium tuberculosis
11/26/2009	WO2009143224A2 Method for the treatment or prophylaxis of lymphangioleiomyomatosis (lam) and animal model for use in lam research
11/26/2009	WO2009143211A2 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
11/26/2009	WO2009143183A1 Pyrimidine non-classical cannabinoid compounds and related methods of use
11/26/2009	WO2009143182A1 Pyrimidine classical cannabinoid compounds and related methods of use
11/26/2009	WO2009143180A1 Pyridine non-classical cannabinoid compounds and related methods of use
11/26/2009	WO2009143179A1 Pyridine classical cannabinoid compounds and related methods of use
11/26/2009	WO2009143175A2 Sensory-specific local anesthesia and prolonged duration local anesthesia
11/26/2009	WO2009143174A2 Chemical permeation enhancers enhance nerve blockade by toxins
11/26/2009	WO2009143153A1 Substituted pyrrolidine amides as modulators of the histamine h3 receptor
11/26/2009	WO2009143150A2 Intestinal alkaline phosphatase modulators and uses thereof
11/26/2009	WO2009143133A2 Compositions and methods to protect cells by blocking entry of pathogen proteins
11/26/2009	WO2009143078A2 Methods of treating brain cancer using hexose compounds
11/26/2009	WO2009143064A2 Rice bran extracts for inflammation and methods of use thereof
11/26/2009	WO2009143058A1 Bicyclic compounds having activity at the cxcr4 receptor
11/26/2009	WO2009143051A1 Substituted imidazopyr-and imidazotri-azines
11/26/2009	WO2009143049A1 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
11/26/2009	WO2009143039A2 Heterocyclic compounds as factor ixa inhibitors
11/26/2009	WO2009143024A2 Compounds and methods for kinase modulation, and indications therefor
11/26/2009	WO2009143021A1 Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
11/26/2009	WO2009143020A1 Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
11/26/2009	WO2009143019A2 Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity
11/26/2009	WO2009143018A2 Compounds and methods for kinase modulation, and indications therefor
11/26/2009	WO2009143011A1 Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
11/26/2009	WO2009143010A1 Method for treating hyponatremia employing an sglt2 inhibitor and composition containing same
11/26/2009	WO2009142993A1 Topical application of analgesic for pain relief
11/26/2009	WO2009142988A2 Chitin micro-particles as an adjuvant
11/26/2009	WO2009142969A1 Therapeutic lactams
11/26/2009	WO2009142968A2 Valproic acid salts
11/26/2009	WO2009142967A1 Therapeutic prostaglandin compounds used as ocular hypotensive agents
11/26/2009	WO2009142950A1 Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer
11/26/2009	WO2009142902A1 Androgen treatment in females
11/26/2009	WO2009142892A1 Methods and compositions comprising novel cationic lipids
11/26/2009	WO2009142842A2 Novel macrocyclic inhibitors of hepatitis c virus replication
11/26/2009	WO2009142827A2 Compounds and methods for the treatment of viral infection
11/26/2009	WO2009142772A2 Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
11/26/2009	WO2009142771A2 Salts of (r)-5-(2-phenylsulphonylethenyl)-3-(n- methylpyrrolidin-2-ylmethyl)-1h-indole, 5-bromo-3-[(r)-1- methyl-pyrrolidin-2- ylmethyl]-1h-indole and of eletriptan
11/26/2009	WO2009142760A1 Antimicrobial compositions and methods of use
11/26/2009	WO2009142732A2 Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
11/26/2009	WO2009142731A2 Niacin and nsaid combination therapy
11/26/2009	WO2009142713A1 Methods for reducing lipid absorption by an animal
11/26/2009	WO2009142699A1 Treatment of heart failure in women
11/26/2009	WO2009142594A1 The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders
11/26/2009	WO2009142589A1 Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
11/26/2009	WO2009142588A1 Combination of (a) a chemokine receptor 1 (ccr1) antagonist and (b) glucocorticoid receptor modulator
11/26/2009	WO2009142587A1 Method of treating anxious major depressive disorder
11/26/2009	WO2009142571A1 Phenyl and benzodioxinyl substituted indazoles derivatives
11/26/2009	WO2009142569A1 Phenyl or pyridinyl substituted indazoles derivatives
11/26/2009	WO2009142568A1 Combination of (a) glucocorticoid receptor modulator and (b) a b2-agonist
11/26/2009	WO2009142428A2 Pharmaceutical composition for the treatment of premature ejaculation
11/26/2009	WO2009142328A1 Camptothecin polymer derivative and uses of the same
11/26/2009	WO2009142326A1 Docetaxel polymer derivative, method for producing same and use of same
11/26/2009	WO2009142321A1 Novel thiophenediamine derivative having urea structure
11/26/2009	WO2009142271A1 Cancer stem cell having high level of sld5 expression therein
11/26/2009	WO2009142242A1 Composition for preventing cardiovascular event in high-risk patient
11/26/2009	WO2009142195A1 Agent for induction/maintenance of remission
11/26/2009	WO2009141827A2 A conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions
11/26/2009	WO2009141821A1 Separation of polysaccharides by charge density gradient
11/26/2009	WO2009141786A2 Anti-inflammatory compounds

1 ... 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 ... 7860